Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

Article Details

Citation
Copy to clipboard

Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

Expert Opin Pharmacother. 2011 Dec;12(17):2737-50. doi: 10.1517/14656566.2011.633511.

PubMed ID
22077833 [ View in PubMed
]
Abstract

INTRODUCTION: Hospital-acquired pneumonia is a common infection, associated with substantial mortality. Despite the increasing prevalence of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA), approved treatment options for this pathogen are limited. AREAS COVERED: This article reviews the pharmacokinetics, dosing, preclinical studies and clinical efficacy, and safety of telavancin, with a particular focus on results from trials in nosocomial pneumonia. PubMed and Congress websites were searched for relevant articles published between 2003 and 2010. EXPERT OPINION: Telavancin is a lipoglycopeptide antibiotic with rapid, bactericidal activity against MRSA, and may provide another option for the treatment of nosocomial pneumonia, owing to Gram-positive pathogens.

DrugBank Data that Cites this Article

Drugs